Cytotoxicity of voriconazole on cultured human corneal endothelial cells

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4519-4523

  Han, Sang Beom ^a,b   Shin, Young Joo ^c   Hyon, Joon Young ^a,b   Wee, Won Ryang ^b,d  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Hallym University College of Medicine   (South Korea)

^d Seoul National University Biomedical Research Institute   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN ZO1; VORICONAZOLE;

ADULT; APOPTOSIS; ARTICLE; CELL MEMBRANE; CELL VIABILITY; CONTROLLED STUDY; CORNEA CELL; CORNEAL ENDOTHELIAL CELLC; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG SCREENING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TOXICITY TESTING;

APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COLORING AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, CORNEAL; FLOW CYTOMETRY; HUMANS; MEMBRANE PROTEINS; NECROSIS; PHOSPHOPROTEINS; PROPIDIUM; PYRIMIDINES; TRIAZOLES;

EID: 80052824529     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00569-11     Document Type: Article

References (36)

1. Al-Badriyeh, D., L. Leung, G. E. Davies, K. Stewart, and D. Kong. 2009. Successful salvage treatment of Scedosporium apiospermum keratitis with topical voriconazole after failure of natamycin. Ann. Pharmacother. 43:1139-1142.
2. Bednarz, J., M. Teifel, P. Friedl, and K. Engelmann. 2000. Immortalization of human corneal endothelial cells using electroporation protocol optimized for human corneal endothelial and human retinal pigment epithelial cells. Acta Ophthalmol. Scand. 78:0-136.
3. Berge, M., et al. 2011. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. Eur. J. Clin. Pharmacol. 67:253-260.
4. Cho, K. S., E. H. Lee, J. S. Choi, and C. K. Joo. 1999. Reactive oxygen species-induced apoptosis and necrosis in bovine corneal endothelial cells. Invest. Ophthalmol. Vis. Sci. 40:911-919.
5. Cuenca-Estrella, M., B. Ruiz-Diez, J. V. Martinez-Suarez, A. Monzon, and J. L. Rodriguez-Tudela. 1999. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J. Antimicrob. Chemother. 43:9-151.
6. den Hollander, J. G., et al. 2006. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. J. Antimicrob. Chemother. 57:1248-1250.
7. Engelmann, K., M. Bohnke, and P. Friedl. 1988. Isolation and long-term cultivation of human corneal endothelial cells. Invest. Ophthalmol. Vis. Sci. 29:56-1662.
8. Gao, H., et al. 2004. Intravitreal voriconazole: an electroretinographic and histopathologic study. Arch. Ophthalmol. 122:87-1692.
9. Ghannoum, M. A., and D. M. Kuhn. 2002. Voriconazole - better chances for patients with invasive mycoses. Eur. J. Med. Res. 7:242-256.
10. Ghannoum, M. A., and L. B. Rice. 1999. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 12:1-517.
11. Hariprasad, S. M., et al. 2004. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch. Ophthalmol. 122:47.
12. Ishiyama, M., et al. 1996. A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol. Pharm. Bull. 19:1518-1520.
13. Johnson, E., A. Espinel-Ingroff, A. Szekely, H. Hockey, and P. Troke. 2008. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies. Int. J. Antimicrob. Agents 32:1-514.
14. Johnson, L. B., and C. A. Kauffman. 2003. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. 36:630-637.
15. Joyce, N. C., and C. C. Zhu. 2004. Human corneal endothelial cell proliferation: potential for use in regenerative medicine. Cornea 23:S8-S19.
16. Kernt, M., and A. Kampik. 2009. Intracameral voriconazole: in vitro safety for human ocular cells. Toxicology 258:84-93.
17. Kernt, M., A. S. Neubauer, H. M. De Kaspar, and A. Kampik. 2009. Intravitreal voriconazole: in vitro safety-profile for fungal endophthalmitis. Retina 29:2-370.
18. Kramer, M., et al. 2006. Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis. Ophthalmology 113:1184-1186. (Pubitemid 43947229)
19. Lazarus, H. M., J. L. Blumer, S. Yanovich, H. Schlamm, and A. Romero. 2002. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J. Clin. Pharmacol. 42:395-402.
20. Levin, M. D., et al. 2007. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J. Antimicrob. Chemother. 60:04-1107.
21. Lin, R. C., N. Sanduja, and S. M. Hariprasad. 2008. Successful treatment of postoperative fungal endophthalmitis using intravitreal and intracameral voriconazole. J. Ocul. Pharmacol. Ther. 24:5-248.
22. Linares, M. J., et al. 2005. Susceptibility of filamentous fungi to voriconazole tested by two microdilution methods. J. Clin. Microbiol. 43:0-253.
23. Maxwell, M. J., et al. 2003. Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood. J. Clin. Microbiol. 41:1087-1090.
24. Perfect, J. R., et al. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36:22-1131.
25. Pfaller, J. B., S. A. Messer, R. J. Hollis, D. J. Diekema, and M. A. Pfaller. 2003. In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs. J. Clin. Microbiol. 41:26-1129.
26. Pfaller, M. A., et al. 2003. Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole. J. Clin. Microbiol. 41:1875-1880.
27. Reis, A., et al. 2000. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br. J. Ophthalmol. 84:2-933.
28. Sen, P., L. Gopal, and P. R. Sen. 2006. Intravitreal voriconazole for drug-resistant fungal endophthalmitis: case series. Retina 26:935-939.
29. Shen, Y. C., et al. 2009. Pharmacokinetics of intracameral voriconazole injection. Antimicrob. Agents Chemother. 53:2156-2157.
30. Shen, Y. C., et al. 2007. Clearance of intravitreal voriconazole. Invest. Ophthalmol. Vis. Sci. 48:2238-2241.
31. Thiel, M. A., A. S. Zinkernagel, J. Burhenne, C. Kaufmann, and W. E. Haefeli. 2007. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob. Agents Chemother. 51:9-244.
32. Vemulakonda, G. A., et al. 2008. Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. Arch. Ophthalmol. 126:18-22.
33. Vermes, I., C. Haanen, H. Steffens-Nakken, and C. Reutelingsperger. 1995. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 184:39-51.
34. Warrilow, A. G., et al. 2010. Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51). Antimicrob. Agents Chemother. 54:4235-4245.
35. Yilmaz, S., M. Ture, and A. Maden. 2007. Efficacy of intracameral amphotericin B injection in the management of refractory keratomycosis and endophthalmitis. Cornea 26:398-402. (Pubitemid 46684377)
36. Yoeruek, E., et al. 2008. Toxic effects of recombinant tissue plasminogen activator on cultured human corneal endothelial cells. Invest. Ophthalmol. Vis. Sci. 49:1392-1397.